Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Xencor Inc (XNCR) today and set a price target of $40. The company’s shares opened today at $32.50. Young commented: “. We reiterate our Overweight rating and $40 price target. We think Xencor’s collaboration and license agreement with Astellas (ALPMF, NC) marks another source of […]

“For a long time, Sörmlands Media has tried to get information from all the county’s municipalities on how the spread of infection in elderly care looks, how extensive it is and where it is located. The municipalities have replied that they lack

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech (MBRX), with a price target of $3. The company’s shares opened today at $1.27. McCarthy commented: “Following last month’s clearance to begin its European clinical trial of WP1220 (STAT3 inhibitor) in the topical treatment of cutaneous T-cell lymphoma […]